A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of RPTR-168 in Patients With Relapsed/Refractory HPV-16 E6/E7 Positive Tumors and Melanoma
Latest Information Update: 08 Dec 2022
At a glance
- Drugs RPTR 168 (Primary)
- Indications Cervical cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Repertoire Immune Medicines
- 02 Dec 2022 Status changed from active, no longer recruiting to discontinued.
- 30 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2021 According to a Repertoire Immune Medicines media release, first patient has been dosed at HonorHealth Research and Innovation Institute in Scottsdale, Arizona.